When compared to healthy individuals, the proportion of CD3+ cells in tumor patients' PBMC significantly dropped (P <0.0001), but the proportion of CD14+ cells and CD3-CD16+CD56+ cells remarkably increased (P <0.0001, P =0.0037) (Fig. 2). The gene discussed is CD14; the disease is neoplasm.